




Pegaptanib

Revised: November 15, 2021.

CASRN: 222716-86-1



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of pegaptanib during breastfeeding. Pegaptanib inhibits vascular endothelial growth factor (VEGF). Since VEGF is present in human milk and is thought to help in maturation of the infant's gastrointestinal tract, concern has been raised about the maternal use of VEGF inhibitors during breastfeeding. Note that the typical alternative to breastmilk is infant formula, which contains no VEGF. Until more data are available, pegaptanib should only be used with careful infant monitoring during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Pegaptanib

CAS Registry Number

222716-86-1

Drug Class

Breast Feeding

Lactation

Aptamers, Nucleotide